Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent developments in cathepsin K inhibitor design.

Urszula Grabowskal1, Timothy J Chambers, Masahiro Shiroo

  • 1Medivir UK Ltd, Chesterford Research Park, Little Chesterford, CB10 1XL, UK. urszula.grabowska@medivir.com

Current Opinion in Drug Discovery & Development
|September 15, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Erratum to 'Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts'.

Bone·2021
Same author

Urocortin is a novel regulator of osteoclast differentiation and function through inhibition of a canonical transient receptor potential 1-like cation channel.

The Journal of endocrinology·2011
Same author

The resorptive apparatus of osteoclasts supports lysosomotropism and increases potency of basic versus non-basic inhibitors of cathepsin K.

Bone·2010
Same author

Cathepsin K inhibitors prevent matrix-derived growth factor degradation by human osteoclasts.

Bone·2007
Same author

Regulation and enzymatic basis of bone resorption by human osteoclasts.

Clinical science (London, England : 1979)·2007
Same author

A novel assay for analysis of the regulation of the function of human osteoclasts.

Journal of translational medicine·2006

Cathepsin K inhibitors prevent bone loss by targeting osteoclasts, promoting bone formation and strength. This review covers advances in reversible cathepsin K inhibitor design since 2004.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Bone Biology

Background:

  • Cathepsin K is crucial for bone resorption, being highly expressed in osteoclasts.
  • Osteoclast-specific Cathepsin K activity drives bone degradation.
  • Inhibitors of Cathepsin K offer a novel therapeutic approach for bone loss.

Purpose of the Study:

  • To review the advancements in reversible Cathepsin K inhibitor design.
  • To highlight the role of Cathepsin K in bone metabolism.
  • To discuss the development of assays and models for Cathepsin K inhibitor research.

Main Methods:

  • Literature review of scientific publications and patents.
  • Analysis of structure-activity relationships for reversible Cathepsin K inhibitors.
  • Evaluation of cell-based assays and animal models used in inhibitor development.

Related Experiment Videos

Main Results:

  • Cathepsin K inhibitors represent a new class of antiresorptive agents.
  • These inhibitors prevent bone loss while preserving or enhancing bone formation.
  • Recent designs focus on reversible inhibition mechanisms.

Conclusions:

  • Cathepsin K inhibitors hold significant therapeutic potential for bone diseases.
  • Effective drug development relies on robust preclinical models and assays.
  • Continued research in reversible inhibitor design is advancing bone-protective therapies.